Index of artpub/2024/311555/

Llibre, Josep M
Long-term safety and impact of immune recovery in heavily treatment-experienced adults receiving fostemsavir for up to 5 years in the phase 3 BRIGHTE study
2024
https://ddd.uab.cat/record/311555